Thyrocare Technologies Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹193Cr
- +22.9% YoY
- +3.2% QoQ
- Net profit
- ₹38Cr
- +58.3% YoY
- +72.7% QoQ
- Margin
- 30%
- +3 pp YoY
- 0 pp QoQ
Guidance rank: #16 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum. Thyrocare expects to maintain EBITDA margins around 30%, with any excess reinvested into the business to drive growth.
From Thyrocare Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum.
- Expectation to add 1,200 to 1,500 new franchises during the year, maintaining approximately 100 franchise additions per month.
- Growth driven by both organic expansion (21% in Q1) and inorganic growth via acquisitions (around 2%).
- Strong focus on increasing franchisee revenue, which grew 20% YoY in Q1 FY26.
- Partnership revenue grew 36% YoY in Q1, with ongoing expansion in health check segments and onboarding new clients.
- Expansion of franchise footprint pan-India, with secular growth spread across regions, avoiding concentration in any single geography.
2 more points from Thyrocare Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investment of approximately ₹3 to ₹4 lakh is required to set up a franchise collection center, including infrastructure like boards, mirrors, and sample collection area.
- Franchise deposit is minimal and mostly provided by about 10% of franchisees with boards; the deposit is refunded as wallet balance used for business.
- Thyrocare is moving towards a CAPEX model for equipment procurement in pathology labs, capitalizing machines on their books instead of reagent rental (RR) model.
- Recent acquisitions (Polo Lab, Vimta Clinical Diagnostics, Think Health) are fully integrated, supporting strategic expansion in North and South India.
2 more points from Thyrocare Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Thyrocare Technologies Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 193 | 157 | +22.9% | 187 | +3.2% |
| Operating profit (EBITDA) | 58 | 42 | +38.1% | 57 | +1.8% |
| Operating margin | 30% | 27% | +3 pp | 30% | 0 pp |
| Profit before tax | 50 | 34 | +47.1% | 47 | +6.4% |
| Net profit (PAT) | 38 | 24 | +58.3% | 22 | +72.7% |
| EPS (₹) | 2.45 | 1.52 | +61.2% | 1.36 | +80.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Technologies's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene International (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q1 FY26 results?
Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum. Thyrocare expects to maintain EBITDA margins around 30%, with any excess reinvested into the business to drive growth.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
Investment of approximately ₹3 to ₹4 lakh is required to set up a franchise collection center, including infrastructure like boards, mirrors, and sample collection area.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
